Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?

Baroudjian B, Boussemart L, Routier E, Dreno B, Tao Y, Deutsch E, Blanchard P, Dhermain F, Vilcot L, Vagner S, Eggermont A, Mateus C, Robert C.

Eur J Dermatol. 2014 Mar-Apr;24(2):265-7. doi: 10.1684/ejd.2014.2300. No abstract available.

PMID:
24721778
2.

Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.

Seeley AR, De Los Santos JF, Conry RM.

Melanoma Res. 2015 Jun;25(3):246-51. doi: 10.1097/CMR.0000000000000154.

PMID:
25746037
3.

Vemurafenib therapy for stage IV melanoma with V600G-mutation.

Lang N, Weisser A, Enk A, Hassel JC.

J Dtsch Dermatol Ges. 2013 Dec;11(12):1198-9. doi: 10.1111/ddg.12200. Epub 2013 Sep 9. No abstract available.

PMID:
24016000
4.

Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?

Saint-Jean M, Quéreux G, Nguyen JM, Peuvrel L, Brocard A, Vallée A, Knol AC, Khammari A, Denis MG, Dréno B.

J Invest Dermatol. 2014 May;134(5):1468-1470. doi: 10.1038/jid.2013.378. Epub 2013 Sep 11. No abstract available.

5.

BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.

Lebbé C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, Pages C, Roux J, Porcher R, Tost J, Mourah S.

Melanoma Res. 2014 Aug;24(4):415-8. doi: 10.1097/CMR.0000000000000088. No abstract available.

PMID:
24933605
6.

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.

Nijenhuis CM, Huitema AD, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH.

J Clin Pharmacol. 2017 Jan;57(1):125-128. doi: 10.1002/jcph.788. Epub 2016 Jul 29. No abstract available.

PMID:
27365214
7.

[Radiosensitization induced by vemurafenib].

Ducassou A, David I, Delannes M, Chevreau C, Sibaud V.

Cancer Radiother. 2013 Jul-Aug;17(4):304-7. doi: 10.1016/j.canrad.2013.04.004. Epub 2013 Jun 27. French.

PMID:
23810304
8.

Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.

Starz H, Gutschi M, Welzel J, Haas C.

J Dtsch Dermatol Ges. 2014 Feb;12(2):151-4. doi: 10.1111/ddg.12231. Epub 2013 Nov 18. No abstract available.

PMID:
24238398
9.

Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.

Koers K, Francken AB, Haanen JB, Woerdeman LA, van der Hage JA.

J Clin Oncol. 2013 Jun 1;31(16):e251-3. doi: 10.1200/JCO.2012.45.3845. Epub 2013 Apr 8. No abstract available.

PMID:
23569313
10.

Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.

Owen JL, Lopez IE, Desai SR.

J Drugs Dermatol. 2015 May;14(5):509-10.

PMID:
25942671
11.

Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.

Gabeff R, Dutartre H, Khammari A, Boisrobert A, Nguyen JM, Quereux G, Brocard A, Saint-Jean M, Peuvrel L, Dreno B.

Eur J Dermatol. 2015 Sep-Oct;25(5):452-6. doi: 10.1684/ejd.2015.2628.

PMID:
26242321
12.

Toxic epidermal necrolysis induced by vemurafenib.

Lapresta A, Dotor A, González-Herrada C.

Actas Dermosifiliogr. 2015 Oct;106(8):682-3. doi: 10.1016/j.ad.2015.03.008. Epub 2015 Jun 4. English, Spanish. No abstract available.

PMID:
26051238
13.

Community experience of vemurafenib for BRAF(V600) melanoma.

Hersey P.

Lancet Oncol. 2014 Apr;15(4):369-70. doi: 10.1016/S1470-2045(14)70079-8. Epub 2014 Feb 27. No abstract available.

PMID:
24582506
14.

Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.

Anker CJ, Ribas A, Grossmann AH, Chen X, Narra KK, Akerley W, Andtbacka RH, Noyes RD, Shrieve DC, Grossmann KF.

J Clin Oncol. 2013 Jun 10;31(17):e283-7. doi: 10.1200/JCO.2012.44.7755. Epub 2013 May 6. No abstract available.

PMID:
23650406
15.

To B-(RAF) or not to be.

Dummer R, Goldinger SM, Widmer D, Dreier J, Levesque MP.

J Invest Dermatol. 2014 May;134(5):1200-1201. doi: 10.1038/jid.2014.62.

16.

Melanoma brain metastases and vemurafenib: need for further investigation.

Rochet NM, Dronca RS, Kottschade LA, Chavan RN, Gorman B, Gilbertson JR, Markovic SN.

Mayo Clin Proc. 2012 Oct;87(10):976-81. doi: 10.1016/j.mayocp.2012.07.006.

17.

Absent response of intracranial melanoma metastases harboring BRAF V600E sequence variation to vemurafenib.

D'Alonzo D, Glatz K.

Mayo Clin Proc. 2013 Dec;88(12):e151-2. doi: 10.1016/j.mayocp.2013.04.033. No abstract available.

PMID:
24290130
18.

Vemurafenib and radiosensitization.

Boussemart L, Boivin C, Claveau J, Tao YG, Tomasic G, Routier E, Mateus C, Deutsch E, Robert C.

JAMA Dermatol. 2013 Jul;149(7):855-7. doi: 10.1001/jamadermatol.2013.4200.

PMID:
23699661
19.

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU.

Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27.

PMID:
24582505
20.

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.

Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD.

Eur J Cancer. 2014 Feb;50(3):611-21. doi: 10.1016/j.ejca.2013.11.002. Epub 2013 Nov 29.

PMID:
24295639

Supplemental Content

Support Center